Q1 Earnings Snapshot:-----> $DIVISLAB & $MUTHOOTFIN Deliver Strong Numbers. Here's What you Need to Know.

Two quality companies from different sectors reported impressive Q1 results, with both posting robust growth in revenue and profitability. Here's a quick snapshot: Q1 Results : $DIVISLAB Net Profit Rises 65.5% Divi's Laboratories Q1 Results - Cons, YoY Net profit up 65.5% at Rs 902 crore vs Rs 545 crore YoY Revenue up 27.8% at Rs 3,080 crore vs Rs 2,410 crore YoY EBITDA up 72.2% at Rs 1,255 crore vs Rs 729 crore YoY EBITDA margin at 40.7% vs 30.2% YoY ----->Key Takeaways • Strong operating leverage drove EBITDA growth well ahead of revenue growth. • EBITDA margin expanded sharply to 40.7%, reflecting improved profitability. • Net profit surged 65.5%, making it one of the strongest performances in the pharma sector this earnings season. ##Q1 Results : $MUTHOOTFIN Profit Rises 39%, Total Income Up 35% Muthoot Finance – Q1 (Consolidated,YoY) Profit up 38.8% to Rs 2,799 crore versus Rs 2,016 crore Total Income up 34.5% to Rs 8,695 crore versus Rs 6,466 crore To Promote K R Bijimon To CEO Post From Oct. 1 ------->Other Key Updates • The company announced the promotion of K. R. Bijimon as CEO, effective 1 October. Key Takeaways • Strong growth in income reflects continued momentum in the gold loan business. • Profit growth of nearly 39% highlights resilient demand and healthy operating performance. ##Stocks in Focus • $DIVISLAB • $MUTHOOTFIN • $AUROPHARMA • $DRREDDY • $MANAPPURAM -------->Bottom Line The Q1 earnings season continues to deliver positive surprises. Divi's Laboratories impressed with exceptional margin expansion and a 65.5% jump in profit, while Muthoot Finance maintained its strong growth trajectory with nearly 39% profit growth.